Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection,...
Doer Biologics
Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study
Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary Doer Biologics has received National...
Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia
Huadong Medicine (SHE: 000963) announced that the Investigational New Drug (IND) application for DR10624 Injection,...
Doer Biologics Begins Phase II Study of DR10624 for Steatotic Liver Disease
China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...
Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies
China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...
Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs
Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing...
Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...